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Heart failure is increasing worldwide at epidemic
proportions, resulting in considerable disability, mortality,
and increase in healthcare costs. Gated myocardial
perfusion single photon emission computed tomography or
PET imaging is the most prominent imaging modality
capable of providing information on global and regional
ventricular function, the presence of intraventricular
synchronism, myocardial perfusion, and viability on the
same test. In addition, 123I-mIBG scintigraphy is the only
imaging technique approved by various regulatory agencies
able to provide information regarding the adrenergic
function of the heart. Therefore, both myocardial perfusion
and adrenergic imaging are useful tools in the workup and
management of heart failure patients. This guide is intended
to reinforce the information on the use of nuclear cardiology
techniques for the assessment of heart failure and
associated myocardial disease. Nucl Med Commun
35:818–823 © 2014 Wolters Kluwer Health | Lippincott
Williams & Wilkins.
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Introduction
Heart failure (HF) is growing globally at epidemic pro-
portions, causing considerable increases in disability and
mortality as well as in healthcare costs [1,2]. Coronary
artery disease (CAD), diabetes mellitus, and hyperten-
sion are major etiological risk factors. HF affects more
than 15 million people worldwide [2]. Dilated cardio-
myopathy (DCM) refers to a heterogeneous spectrum of
myocardial diseases that are characterized by ventricular
dilation and reduced myocardial contractility. Once
patients become symptomatic, the prognosis is relatively
poor, with 25% mortality at 1 year and 50% mortality at
5 years [3]. Among the causes of acquired DCM in Latin
America, Chagas cardiomyopathy is one of the most
common, with a prevalence of ∼ 24 million [4] of HF in
areas where the disease is endemic. Given the morbidity
and mortality from HF, as well as the considerable
resources that are used to diagnose and treat these
patients, appropriate diagnosis and prognosis assessment
are vital.
Gated myocardial perfusion 99mTc single photon emis-
sion computed tomography (SPECT) or PET imaging
(MPI) is the most prominent imaging modality capable of
providing, in a reproducible manner, information on
global and regional ventricular function, the presence of
intraventricular synchronism, myocardial perfusion,
and viability on the same test. In addition, 123I-mIBG
scintigraphy is the only imaging technique approved by
various regulatory agencies able to provide information
regarding the adrenergic function of the heart. Therefore,
both adrenergic imaging and MPI are useful tools in the
workup and management of HF patients.
Results from a worldwide meta-analysis of all pertinent
clinical trials up to 2007 suggest that ∼ 1–3% of all
patients discharged alive after hospitalization for HF and
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15–20% of all patients seen in HF clinics meet cardiac
resynchronization therapy (CRT) eligibility criteria [5];
thus, all of these patients could be candidates for MPI
dyssynchrony analysis. As about half of these numbers
also meet the criteria for implantable cardiac defibrillator
(ICD) implantation [5], it is also prudent to consider
imaging these patients with 123I-mIBG as an adjunct to
their risk stratification for treatment selection. The spe-
cific number of HF patients who would benefit from
undergoing these imaging techniques for a specific
country is thus dependent on accurate statistics in terms
of the total number of HF patients seen in clinics, which
is a difficult number to obtain, depending on the country.
It is estimated that HF affects 23 million people world-
wide [6].
This guidance is a consensus statement from an inter-
national panel of nuclear medicine experts assembled by
the International Atomic Energy Agency (IAEA). The
initial purpose was to address how to use our techniques
to help manage patients with Chagas disease, but the
focus quickly transitioned to the topic of addressing the
potential use of nuclear medicine techniques in all
patients with HF. This guidance is intended to reinforce
the information on the use of available nuclear cardiology
techniques for the assessment of HF and associated
myocardial disease. This article is not intended as an
exhaustive review of all data on the subject of HF ima-
ging but rather as a consensus statement of experts with
knowledge on the existing evidence, mainly addressed to
developing countries with limited resources. Because
PET radiopharmaceuticals used in HF assessment are
not widely available the panel focused on scintigraphic
planar and SPECT procedures.
Why should a heart failure patient be sent for
nuclear imaging?
The prevalence of heart failure is increasing in both
developed and developing countries. Ischemic cardio-
myopathy is the most common etiology of chronic HF
[1]. The initial clinical management decision in HF
patients is based on the differentiation of ischemic from
nonischemic etiologies. Among a variety of diagnostic
approaches including cardiac catheterization and several
noninvasive imaging techniques, nuclear cardiology
techniques such as MPI and 123I-mIBG imaging have an
important role in the diagnostic workup and risk assess-
ment of patients with HF.
Myocardial perfusion imaging
Recent recommendations [7] and appropriate use criteria
state that nuclear cardiology techniques are adequate in
patients with new-onset or newly diagnosed HF [8]. The
main indication for MPI in the HF population is for the
identification of patients who may benefit from therapy
for myocardial ischemia and ventricular dysfunction,
which includes medical treatment, revascularization, and
resynchronization devices.
Cardiac resynchronization therapy
CRT is a biventricular pacemaker with a third electrode
attached to the left ventricle to assist in resynchronizing
the mechanical contraction of the left ventricular (LV).
CRT has been shown to benefit some patients with end-
stage HF, depressed left ventricular ejection fraction
(LVEF) (< 35%), and a wide QRS complex on the sur-
face ECG (>120 ms [9] or even > 150 ms [10]), and is
now standard treatment for HF [10]. As electrical acti-
vation is often decoupled from the onset of mechanical
contraction, the main indication for MPI in patients being
considered for CRT is for the identification of LV
mechanical dyssynchrony and for guiding the placement
of the LV lead to the last viable contracting segment for
optimal response (improvement of LV function) [11].
The specific reasons why a patient with heart failure
should be referred to nuclear cardiology myocardial per-
fusion imaging:
(1) To assess myocardial ischemia.
(2) To assess LV global and regional viability.
(3) To assess whether LV function is preserved, includ-
ing regional wall motion and thickening, LVEF, LV
volumes, and myocardial LV mass.
(4) To assess LV eccentricity [12].
(5) To assess LV intraventricular dyssynchrony [13,14].
(6) To assess the last viable segment to contract in
patients being considered for CRT [15].
In addition, assessing patients’ risk of cardiac death
contributes to the determination of the probability of
sudden death and the need for an ICD [16].
123I-mIBG imaging
Much evidence has accumulated to show that cardiac
autonomic imaging, such as with 123I-mIBG, is a powerful
risk stratification tool for patients with HF [17]. In the
setting of this condition, normal autonomic balance is
disrupted, which is not only evidence of the severity of
the condition but also an indicator of a worsening prog-
nosis [17,18]. With 123I-mIBG imaging, which is based on
a false transmitter analog of norepinephrine, we can
assess cardiac sympathetic innervation.
On the basis of worldwide experience, the EANM
Cardiovascular Committee and the European Council of
Nuclear Cardiology have recently proposed standardized
methods [19], but more work needs to be done in this
regard. The ideal imaging procedures, including patient
preparation, medication holding, dosage of tracer, acqui-
sition protocols, and quantitative methods, are evolving
[20]. At this time, planar 123I-mIBG imaging procedures
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are well established, although more work is needed for
SPECT imaging and comparative analysis with MPI.
123I-mIBG availability is severely limited throughout the
world, being actively used only in specific regions.
Although available in Japan, Europe, and Brazil for a long
time, 123I-mIBG has just been recently approved in the
USA by the FDA for HF evaluation.
Multiple studies have shown that 123I-mIBG imaging,
especially determination of the heart-to-mediastinum (H/
M) ratio, very effectively separates high-risk from low-
risk patients, regardless of LVEF and NYHA clinical
conditions [17,21]. In fact, patients with a normal H/M
ratio have an excellent prognosis despite other abnormal
cardiac parameters, such as LVEF and brain natriuretic
peptide, and on multivariate analysis H/M has con-
sistently been shown to provide independent incre-
mental risk stratification power [17,21]. However, risk
stratification is useful only to the extent that it allows
guidance of therapies that would improve patient out-
come and well-being.
The specific reasons why a patient with heart failure
should be referred to nuclear cardiology 123I-mIBG:
(1) To assess 123I-mIBG cardiac uptake as given by the
H/M ratio [18].
(2) To use the H/M ratio to help risk stratify the
patient [21].
(3) To use the H/M ratio in risk stratification to help
decide on a change of management decision. For
example, the condition of an HF patient without ICD
has changed and now ICD is being considered [22].
Radiation burden
Concerns about medical exposure to ionizing radiation in
cardiac patients have become heightened in recent years
as a result of rapid growth in procedure volumes and the
high radiation doses incurred from some procedures.
Although several landmark epidemiological studies
involving similar levels of radiation exposure show
increased cancer risk, no strong data currently relate
ionizing radiation specifically from cardiac imaging to
increased risks of cancer [23]. Important benefits of car-
diac imaging for adequate patient management, such as
correct diagnosis, accurate prognostication, and
improvement of outcomes, should also be taken into
account.
In general, radiation dose is less of a concern in elderly
patients with HF because the risk of dying from heart
disease is far greater than any radiation concern. Patients
admitted to hospital with a diagnosis of cancer often have
a longer survival compared with those with a diagnosis of
HF. Prognosis in HF that requires hospitalization can be
considered far worse than that of many common types of
cancer. For example, in the Framingham cohort, 62 and
75% of men and 38 and 42% of women, respectively,
died within 5 years of being diagnosed with HF [24]. In
comparison, 5-year survival rate from all cancers among
men and women in the USA during the same period was
∼ 50% [24].
Regardless, the least amount of radiation burden for the
patient should always be taken into account for each
specific protocol.
Because of the higher radiation exposure to the patient
from thallium-201, if other tracers are available they
should be considered as alternatives, although the
effective dose (mSv/MBq) has been revised and lowered
by one-third from 2.1E− 01 to 1.4E− 01 [25].
Complementary techniques
Other noninvasive imaging techniques such as echo-
cardiography, computed tomography, and MRI can pro-
vide useful information for both diagnostic and
prognostic purposes in HF patients.
Echocardiography
Transthoracic echocardiography remains the most per-
formed myocardial imaging technique because of its
widespread availability, low cost, and ability to provide
information on valvular function, atrial size, right ven-
tricular size, and contractility. Stress echocardiography,
either with physical stress or with dobutamine, is exten-
sively used to noninvasively detect the presence of CAD,
the most common underlying etiology of DCM. In con-
trast, tissue Doppler imaging techniques [26,27] or, more
recently, speckle-tracking echocardiography has been
used to provide information on LV dyssynchrony before
CRT, as well as to help in the prediction of response to
this therapy [28,29]. Echocardiography is the first ima-
ging test recommended in the ACC/AHA guidelines
[30,31] and in the ESC guidelines for the diagnosis of LV
systolic dysfunction [32].
However, it is important to point out the need for
acceptable echocardiographic windows to precisely
determine these parameters, as well as to emphasize that
the technique is less reproducible than nuclear cardiology
techniques, requiring a considerable level of expertise of
the echocardiographer.
Coronary computed tomography
Coronary computed tomographic angiogram (CCTA)
allows the noninvasive visualization of coronary anatomy
and helps to define plaque morphology. It is currently
considered a well-established tool for evaluating coronary
disease [33,34]. The main strength of CCTA seems to be
the reliable exclusion of atherosclerotic disease because
of its very high negative predictive value, which is par-
ticularly important in patients with intermediate-to-low
CAD pretest probability. Thus, CCTA could be a useful
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tool in excluding CAD as the likely culprit for LV systolic
dysfunction in this setting.
Coronary calcium evaluation is a useful way to non-
invasively assess atherosclerotic burden and provides
some guidance to the clinician for the differential diag-
nosis between a possible ischemic versus nonischemic
etiology for LV systolic dysfunction [35]. Nevertheless,
further studies with larger series of patients are needed to
establish its role in this group of patients.
It is important to point out that the information offered
by CCTA is mainly anatomical and does not include data
regarding the presence or absence of ischemia, which is
of particular interest in case of patients with CAD who
need a revascularization procedure. Nuclear techniques
are very well standardized in this setting, offering valu-
able information on the presence and extension of
ischemia, as well as on the status of the intraventricular
synchronization, very useful in the case of patients
evaluated for CRT.
Cardiac magnetic resonance
Cardiac magnetic resonance (CMR) is a versatile tool
used to assess etiology in congestive heart failure because
of its capability for tissue characterization and simulta-
neous assessment of LV function and wall motion and
the possibility of myocardial viability detection through
the late enhancement gadolinium images, which accu-
rately delineate a scar, a powerful marker of poor prog-
nosis in DCM. CMR has the advantage of not using
ionizing radiation. The American College of Cardiology
and the American College of Radiology have recom-
mended CMR as an appropriate tool for the evaluation of
LV systolic dysfunction of unknown etiology [36].
However, it is a very expensive technique that is not
broadly available in cardiac services, contrary to the
already established nuclear techniques.
Key points
On the basis of the current available evidence, the fol-
lowing points represent our consensus position for gui-
dance on the use of nuclear cardiology techniques for the
assessment of HF and associated myocardial disease:
(1) To assess ischemia, a 1- or 2-day rest–stress protocol
probably with pharmacologic stress and nitrates for
rest should be used. Assessment of viability is
important and should include assessment of scar
burden. Scar burden is defined by the total amount
of scar in the LV expressed as a percentage of the
total LV and is an independent prognostic factor as
well as a variable for treatment choice. If 18F-FDG is
available for viability assessment it should be used,
but in most situations an adequate SPECT MPI can
provide the necessary information.
(2) In HF patients, gating to help measure function is
very important, although these patients have more
gating problems [37]. Only a nongated MPI should be
acquired in patients with atrial fibrillation if rejection
of bad beats is not possible. QC of the R wave
triggering is important. If possible use the R-R
window to reject bad beats. Availability of backward
gating will also improve the accuracy of assessment of
the diastolic parameters.
(3) Physicians should be aware of the differences in
normal values for the functional parameters of the
software being used. Specifically, the report should
include assessment of LVEF, LV end-systolic
volume, transient ischemic dilation, eccentricity,
and LV dyssynchrony. In addition, in patients being
assessed for CRT the report should also include the
last viable segment to contract (Tables 1 and 2).
(4) LV synchrony assessment is important, particularly
for patients being considered for CRT therapy
[13,14]. LV synchrony may be assessed with either
the rest or the stress study, preferably using the study
with the most counts [27]. Synchrony should be
similar for the poststress and rest study if the stress
acquisition is performed at least 1 h after stress [38].
However, if image acquisition is performed closer to
stress then differences in synchrony can be found in
CAD patients [39,40]. Gating should be done with
either 8 or 16 frames per cardiac cycle. All acquisition
parameters used should be the same as standard MPI
acquisition [7]. In processing, care must be taken to
QC the selection of the base throughout the cardiac
cycle as improper selection will lead to measurement
errors. The processing software used should have
been validated for the synchrony parameters used for
evaluation. At this time the SD and histogram
bandwidth of the LV phase histogram have been
shown to be useful in determining dyssynchrony
[13,14].
(5) It has been shown that 71% of HF patients who fulfill
the CRT criteria respond to the treatment if their
bandwidth is greater than 135° and/or SD is greater
than 43° [41]. It has also been reported that just
having this amount of dyssynchrony is not enough for
a patient to have a positive response to CRT [17].
The following is also important to assure a higher
probability of success to therapy: (i) the patient
should have less than 50% of scar burden [42], and
Table 1 Perfusion parameters that should be reported in
myocardial perfusion imaging studies of heart failure patients
Parameters Format
Ischemia and viability % from total LV myocardium and location
Scar/necrosis % from total LV myocardium and location
Viabilitya More than 50% uptake from maximum wall uptake
LV, left ventricular.
aIf 18F-FDG is used, mismatch criteria for viability should be considered [6].
Nuclear medicine in the management of HF Peix et al. 821
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
(ii) the LV lead should be placed (if technically
possible) in the last viable segment to contract.
(6) Segmental time of onset of contraction may be
evaluated either visually from dynamic phase displays
or preferably through segmental phase histogram
measurements.
(7) Planar gated blood pool images have also been used
for assessment of dyssynchrony [43–45]. The advan-
tage of this approach is that interventricular dyssyn-
chrony can also be assessed, but the disadvantage is
that it is a volumetric approach but not three dimen-
sional. This limitation may be corrected with SPECT
techniques of blood pool imaging, which are inher-
ently three dimensional.
(8) Echocardiography is another option for evaluating LV
dyssynchrony, particularly using the appropriate soft-
ware (three-dimensional speckle tracking) [29,46].
(9) 123I-mIBG is commonly imaged in an anterior planar
view initially (15–30 min after injection) and in
delayed images 4 h later, and optionally with
SPECT imaging [19]. Global cardiac uptake is
expressed as H/M ratio on the delayed images.
With current imaging methods bad prognosis in HF
patients is observed when H/M ratio is under 1.6 in
delayed images; normal values are above this cutoff
(Table 3). Tracer washout between initial and 4 h
delayed images may also be measured, as well as the
extent and severity of regional defect(s) on delayed
tomographic imaging.
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